These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 35496278)
1. Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport. Quach T; Hu L; Han S; Lim SF; Senyschyn D; Yadav P; Trevaksis NL; Simpson JS; Porter CJH Front Pharmacol; 2022; 13():879660. PubMed ID: 35496278 [TBL] [Abstract][Full Text] [Related]
2. Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid. Han S; Quach T; Hu L; Lim SF; Zheng D; Leong NJ; Sharma G; Bonner D; Simpson JS; Trevaskis NL; Porter CJH Mol Pharm; 2023 May; 20(5):2675-2685. PubMed ID: 36996486 [TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334 [TBL] [Abstract][Full Text] [Related]
4. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. Hu L; Quach T; Han S; Lim SF; Yadav P; Senyschyn D; Trevaskis NL; Simpson JS; Porter CJ Angew Chem Int Ed Engl; 2016 Oct; 55(44):13700-13705. PubMed ID: 27482655 [TBL] [Abstract][Full Text] [Related]
5. Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs. Han S; Hu L; Gracia ; Quach T; Simpson JS; Edwards GA; Trevaskis NL; Porter CJ Mol Pharm; 2016 Oct; 13(10):3351-3361. PubMed ID: 27608166 [TBL] [Abstract][Full Text] [Related]
6. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism. Wang X; Zhang C; Han N; Luo J; Zhang S; Wang C; Jia Z; Du S Drug Deliv; 2021 Dec; 28(1):1664-1672. PubMed ID: 34338567 [TBL] [Abstract][Full Text] [Related]
7. Corrigendum: Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transport. Quach T; Hu L; Han S; Lim SF; Senyschyn D; Yadav P; Trevaskis NL; Simpson JS; Porter CJH Front Pharmacol; 2022; 13():1014363. PubMed ID: 36133812 [TBL] [Abstract][Full Text] [Related]
8. The Impact of Conjugation Position and Linker Chemistry on the Lymphatic Transport of a Series of Glyceride and Phospholipid Mimetic Prodrugs. Han S; Quach T; Hu L; Lim SF; Gracia G; Trevaskis NL; Simpson JS; Porter CJH J Pharm Sci; 2021 Jan; 110(1):489-499. PubMed ID: 33069711 [TBL] [Abstract][Full Text] [Related]
9. Efficient Intestinal Digestion and On Site Tumor-Bioactivation are the Two Important Determinants for Chylomicron-Mediated Lymph-Targeting Triglyceride-Mimetic Docetaxel Oral Prodrugs. Tian C; Guo J; Wang G; Sun B; Na K; Zhang X; Xu Z; Cheng M; He Z; Sun J Adv Sci (Weinh); 2019 Dec; 6(24):1901810. PubMed ID: 31871861 [TBL] [Abstract][Full Text] [Related]
10. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. Elz AS; Trevaskis NL; Porter CJH; Bowen JM; Prestidge CA J Control Release; 2022 Jan; 341():676-701. PubMed ID: 34896450 [TBL] [Abstract][Full Text] [Related]
11. Profiling the role of deacylation-reacylation in the lymphatic transport of a triglyceride-mimetic prodrug. Han S; Hu L; Quach T; Simpson JS; Trevaskis NL; Porter CJ Pharm Res; 2015 May; 32(5):1830-44. PubMed ID: 25446770 [TBL] [Abstract][Full Text] [Related]
12. Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug. Han S; Hu L; Quach T; Simpson JS; Trevaskis NL; Porter CJH J Pharm Sci; 2016 Feb; 105(2):786-796. PubMed ID: 26540595 [TBL] [Abstract][Full Text] [Related]
13. Transdermal prodrug concepts: permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles. Imoto H; Zhou Z; Stinchcomb AL; Flynn GL Biol Pharm Bull; 1996 Feb; 19(2):263-7. PubMed ID: 8850319 [TBL] [Abstract][Full Text] [Related]
14. Development of lipophilic ester prodrugs of dolutegravir for intestinal lymphatic transport. Chu Y; Wong A; Chen H; Ji L; Qin C; Feng W; Stocks MJ; Gershkovich P Eur J Pharm Biopharm; 2023 Oct; 191():90-102. PubMed ID: 37634824 [TBL] [Abstract][Full Text] [Related]
15. Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study. Strang J; Reed K; Bogdanowicz K; Bell J; van der Waal R; Keen J; Beavan P; Baillie S; Knight A Eur Addict Res; 2017; 23(2):61-70. PubMed ID: 28268215 [TBL] [Abstract][Full Text] [Related]
16. Long chain triglyceride-lipid formulation promotes the oral absorption of the lipidic prodrugs through coincident intestinal behaviors. Tian CT; Guo JJ; Miao YF; Wang HL; Ye Q; Guo CL; Zhang MY; He ZG; Sun J Eur J Pharm Biopharm; 2022 Jul; 176():122-132. PubMed ID: 35643367 [TBL] [Abstract][Full Text] [Related]
17. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. Griffin BT; O'Driscoll CM J Pharm Pharmacol; 2006 Jul; 58(7):917-25. PubMed ID: 16805951 [TBL] [Abstract][Full Text] [Related]
18. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C; Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007 [TBL] [Abstract][Full Text] [Related]
20. Enhancing Oral Performance of Paclitaxel Lipid-Mimic Prodrug via Modulating Type of Fatty Acids. Miao YF; Ye Q; Zhang MY; Gao L; Wang XY; Zhong WX; Wang ZX; He ZG; Tian CT; Sun J Adv Healthc Mater; 2023 Jul; 12(19):e2203118. PubMed ID: 36929289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]